Pre-market top loser 2211.HK down 83% to HK$0.87 on HKSE: watch HK$0.76 support

2211.HK stock opened pre-market as one of Hong Kong’s top losers after a sharp gap down to HK$0.87, a decline of 83.11% from the prior close of HK$5.15. Volume surged to 14,215,000 shares versus an average of 1,614,497, signalling extreme short-term selling pressure. The move left the share price close to its year low of HK$0.76 and well below the 50-day average of HK$2.14. Traders should treat intraday volatility and liquidity spikes as primary drivers until company news clarifies the drop

2211.HK stock pre-market move and immediate drivers

Universal Health International Group Holding Limited (2211.HK) traded at HK$0.87 in the pre-market on 03 Feb 2026. The one-day change is -83.11% and the session range was HK$0.81–HK$1.04.

There is no company filing in the public feed tied to the gap. Market activity shows extreme volume, with a relative volume of 34.52 versus the 30-day average. Traders should watch communications from the company and HKSE notices for confirmation of any corporate event

Valuation and fundamentals for 2211.HK stock

Universal Health International (2211.HK) reports EPS of -0.36 and a trailing PE of -3.00. The stock trades at PB 0.24, book value per share HK$3.96, and market cap around HK$86,515,392.00.

Revenue per share is HK$8.88 and the current ratio is 1.31, showing modest short-term liquidity. Negative earnings and a negative ROE of -7.91% explain weak earnings metrics despite a low price-to-sales ratio of 0.11

Technicals and short-term trading levels for 2211.HK stock

Momentum indicators show oversold conditions: RSI 17.59 and Williams %R at -100.00. Price sits below the 50-day average HK$2.1424 and 200-day average HK$1.5385, signalling a clear downtrend.

Key levels: immediate support is the year low at HK$0.76; initial resistance sits near HK$1.44 (lower Bollinger band) and stronger resistance at the 200-day average HK$1.54. Elevated on‑balance volume and a surge in trade count increase short‑term volatility

Meyka AI rates 2211.HK with a score out of 100 and forecast

Meyka AI rates 2211.HK with a score out of 100: 60.00, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of HK$4.73 and a yearly price of HK$3.87. Compared with the current price HK$0.87, the yearly projection implies an upside of 345.09% and the monthly projection implies 443.68% upside. Forecasts are model-based projections and not guarantees

Risks, sector context and catalyst timeline for 2211.HK stock

Risk factors include continued investor de‑risking, potential corporate announcements, and low liquidity at sub‑HK$1 levels. Interest coverage is negative, and net income per share is negative at -0.32, heightening earnings risk.

Sector context: Healthcare peers in Hong Kong trade at an average PE of 29.06 and stronger profitability. Watch near-term catalysts: any HKSE disclosure, quarterly earnings communications, or regulatory updates. For competitor comparisons, see market pages Investing.com competitor matrix and sector peer checks Investing.com comparatives

Trading strategy and realistic price targets for 2211.HK stock

Given high volatility, short-term traders may set tight risk controls around the year low HK$0.76. A conservative near-term price target is HK$1.40, aligned with a potential bounce toward the 200-day average.

A medium-term recovery scenario places a stretch target at HK$3.00 if fundamentals improve and liquidity normalises. Any position should use stops and position sizing; this is market analysis, not investment advice. View our tracking page for updates at 2211.HK on Meyka

Final Thoughts

2211.HK stock is a leading pre-market loser on 03 Feb 2026 after a sharp gap to HK$0.87 on extreme volume of 14.22M shares. Fundamentals show a negative EPS of -0.36 and trailing PE of -3.00, while valuation metrics such as PB 0.24 suggest the market values the company well below book. Technical indicators are deeply oversold with RSI 17.59, and key support sits at the year low HK$0.76. Meyka AI’s forecast model projects a yearly price of HK$3.87, implying 345.09% upside from the current price; these model projections are not guarantees. Short-term traders should prioritise verification of corporate disclosures, manage risk actively, and treat any rebound as technical relief unless company fundamentals change materially. For ongoing updates use our Meyka AI-powered market analysis platform and company pages

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.